Contract research organisation (CRO) Domainex has appointed Hayley French as CEO.
French is a qualified attorney with a background in microbiology and significant experience in the life sciences sector.
She possesses a proven track record of fostering growth and innovation, having held leadership positions in multiple pharmaceutical and biotechnology organisations. Her areas of expertise include strategic development, business operations, and commercialisation.
“We are excited to welcome Hayley to Domainex,” remarked Eddy Littler, Chairman of Domainex.
“Her profound understanding of the biotechnology landscape, strategic vision, and exemplary leadership skills render her the ideal individual to steer Domainex through its next stage of growth. We are confident that under her stewardship, Domainex will continue to deliver exceptional value to its clients and partners.”
Prior to her appointment at Domainex, Hayley occupied several senior leadership roles, including Chief Executive Officer of Apitope International NV before its acquisition by Worg Pharmaceuticals.
She has also held legal positions related to pharmaceutical and biotechnology transactions at Novartis and Bird & Bird in London, in addition to serving as the Head of Legal Affairs at CAMR in the UK. Hayley commenced her career at UCL Ventures.
“I am honoured to join Domainex and lead this talented team,” commented Hayley. “Domainex is renowned for its innovative approach to drug discovery and its unwavering commitment to delivering high-quality results. I am eager to collaborate with the Domainex team to build upon this strong foundation and drive further success.”
Hayley's appointment is effective immediately, and she will be based at Domainex's headquarters in Cambridge, UK. Eddy Littler, who has been serving as Chief Executive Officer, will revert to his position as non-executive Chairman.